Metropolis Healthcare hosts 25th IAP-ID Annual CME on current molecular diagnostic practices in clinical oncology

The event had a global participation of more than 250-plus delegates

Metropolis Healthcare hosted the 25th International Academy of Pathology – Indian Division (IAP-ID) Annual CME event in collaboration with the Asian Cancer Institute and Indian Medical Association. The significant Silver Jubilee edition adopted a hybrid format bringing together over 250 delegates from around the world, including pathologists, clinicians, researchers, and healthcare professionals.

The event was graced by esteemed dignitaries including Dr Sujay Prasad, President, IAP-ID, Dr Reeni Malik, Secretary & Treasurer, IAP-ID, Dr Francisco Couto (Vice-President IAP), Dr Pankaj Bhandarkar, President, IMA Mumbai Branch; Dr Ramakant Deshpande, Chief of Thoracic Surgical Oncology, ACI Hospitals, Mumbai and Metropolis Leadership Team, including Ameera Shah, Promoter and MD, Surendran C (CEO), Dr Kirti Chadha (CSO) and Mohan Menon (CMO).

The event, themed “Current Molecular Diagnostic Practices in Clinical Oncology,” provided a valuable platform for advancing knowledge in molecular oncologic pathology. In an ever-evolving landscape where precision medicine is revolutionizing cancer treatment, pathologists play a pivotal role in diagnosing distinct genetic signatures of cancer cases. This CME aimed to empower pathologists with the expertise needed to navigate the intricate terrain of cancer diagnosis treatment and monitoring.

The event’s comprehensive programme featured a full-day CME session and a half-day workshop, offering delegates in-depth knowledge and practical insights into precision oncology. Notable national and international experts led discussions and presentations on novel diagnostic and prognostic tests, with a particular focus on solid organ tumours and hematopoietic malignancies.

Dr Sushil Shah, Founder & Chairman, Metropolis Healthcare, said, “With over four decades in diagnostics, Metropolis Healthcare has consistently embraced cutting-edge tests and technology. Our unwavering commitment to excellence and innovation has propelled us from traditional diagnostics to AI-powered precision diagnostics. Our leadership in medical diagnostics is sustained through substantial investments in advanced technologies, ongoing research, and continuous training.”

Dr Shah further added, “In today’s era of personalized cancer treatment, precise diagnosis based on tumour molecular characteristics is essential for successful therapy. Metropolis recognises the pivotal role of pathologists in this process, and we believe that a platform like IAP-ID Annual CME 2023 will further contribute significantly to enhancing their expertise in molecular oncology.”

Dr Kirti Chadha, Chief Scientific Officer & Senior Oncopathologist, Metropolis Healthcare commented, “The organisation’s mission is to bridge the gap between traditional pathology and cutting-edge molecular oncology. Our goal is to empower pathologists with the tools and understanding needed to provide patients with the best possible care. This CME encourages collaboration and active participation among pathologists, ensuring the advancement of precision oncology in the field of pathology.”

The delegates at the IAP-ID event, both in-person and virtually, represented a diverse and engaged community of professionals dedicated to advancing healthcare. Attendees had the opportunity to learn from leading experts, exchange ideas, and contribute to the future of precision oncology.


Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Back to top button